Sign in
Taking people in United StatesNo phase

Breathing Muscle Training to Lower Blood Pressure in Chronic Kidney Disease

Tests breathing muscle training for high blood pressure in kidney disease.

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora, United StatesSee the site
Trial code
Registry title
Inspiratory Muscle Strength Training in Chronic Kidney Disease
Status
Recruiting
People taking part
108 people, planned
Started
1 Mar 2022
Planned end
1 Jul 2026
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • IMST
  • Sham Training
Record updated
2 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 or older with stage 3 or 4 chronic kidney disease and blood pressure that is not well controlled. It tests breathing muscle strength training to lower systolic blood pressure.

Age
50 years or older
Sex
All sexes; women must be post-menopausal
Disease stage
Chronic kidney disease stage 3 or 4 (eGFR 20-59 mL/min/1.73m^2, stable kidney function in the past 3 months), with inadequately controlled hypertension (systolic blood pressure 120-159 mmHg on two separate days)
Earlier treatment
Must be on a stable blood pressure medicine regimen for the past 6 weeks. Weight must be stable (under 2 kg (4 lb) change) in the prior 3 months. People who take GLP-1 receptor agonists cannot join unless their weight has been stable for at least 3 months.

Main reasons for not taking part

  • Kidney disease needing regular dialysis
  • Significant lung disease, such as COPD, interstitial lung disease, cystic fibrosis or uncontrolled asthma
  • Severe heart failure (ejection fraction under 35%)
  • Current smoker
  • Known cancer

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Aged 50 years or older; women must be post-menopausal
  • Chronic kidney disease stage 3 or 4 (estimated glomerular filtration rate with the 4 CKD-EPI 2021 race-free equation: 20-59 mL/min/1.73m\^2; stable renal function in the past 3 months)
  • History of inadequately controlled hypertension (systolic blood pressure 120-159 mmHg on two separate days) and on a stable antihypertensive regimen for the past 6 weeks
  • Weight stable in the prior 3 months (<2 kg weight change) and willing to remain weight stable throughout the study. Participants using glucagon-like peptide-1 receptor agonists or planning to start them during the study are excluded unless they have achieved weight stability for at least 3 months prior to enrollment
  • Ability to provide informed consent

Who cannot take part

  • Immunosuppressant agents taken in the past 12 months. Steroids used for the treatment of gout are acceptable; however, patients should not be using steroids within 2 weeks (or 14 days) prior to the vascular testing (rationale: may confound vascular testing)
  • Inability to cooperate with or clinical contraindication for magnetic resonance imaging including: severe claustrophobia, implants, devices, or non-removable body piercings (these individuals can participate in the study but are excluded from the MRI procedure)
  • Illicit drug use or alcohol dependence/abuse, which in the opinion of the investigators, would prohibit compliance with the study intervention
  • Patients with advanced chronic kidney disease requiring chronic dialysis
  • Significant pulmonary disorders including: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, or uncontrolled asthma
  • History of spontaneous pneumothorax, collapsed lung due to traumatic injury that has not fully healed, burst eardrum that has not fully healed, or other conditions of the eardrum
  • Significant co-morbid conditions with a life expectancy of < 1 year
  • History of hospitalization within the last month
  • Known malignancy
  • History of severe congestive heart failure (i.e., ejection fraction <35%)
  • Albuminuria (albumin to creatinine ratio > 2200 mg/g
  • Current smoker

Where in United States

  • University of Colorado Anschutz Medical CampusAurora, United StatesContact: Kristen Nowak, PhD, MPHTaking people

About the trial

What the trial wants to find out

More than 80% of individuals with chronic kidney disease have concomitant hypertension and the majority fail to achieve blood pressure control <130/80 mmHg, leading to high risk of cardiovascular diseases and end-stage kidney disease. A stepwise combination of lifestyle modifications and drug therapy is recommended to lower blood pressure; however, adherence to time-intensive lifestyle interventions such as aerobic exercise in patients with chronic kidney disease is poor. This clinical trial seeks to establish the efficacy of high-resistance inspiratory muscle strength training, a novel time-efficient lifestyle intervention, for lowering systolic blood pressure and improving endothelial function in midlife and older adults with moderate-to-severe chronic kidney disease and inadequately controlled hypertension, and to use innovate translational assessments to understand the mechanisms involved.

The 2 groups in the trial

  • IMSTTreatment being tested

    This group will perform high-resistance (75% of maximal inspiratory pressure) inspiratory muscle strength training (IMST), 30 inhalations/session, 6 days/week.

  • ControlSham treatment, for comparison

    This group will perform low-resistance (15% of maximal inspiratory pressure) inspiratory muscle strength training, 30 inhalations/session, 6 days/week.

    Treatment: Sham Training

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure in Midlife and Older Adults With Chronic Kidney Disease
Plain-language title
Breathing Muscle Training to Lower Blood Pressure in Chronic Kidney DiseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
2 May 2025